Keywords: roche, xeloda, effective, costly, regimen, colorectal, cancer

Roche's Xeloda effective as "more costly" regimen in colorectal cancer

Article | 09 July 2007

Print This

Swiss drugmaker Roche says that data presented at the World Congress on Gastrointestinal Cancer in Barcelona, Spain, demonstrate that its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in